Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KZR-261 in advanced solid tumors
NCT05047536Phase 1Terminated
- Sponsor
- Kezar Life Sciences
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kzr-261 in melanoma, Uveal melanoma (UM), mesothelioma and 3 more, sponsored by Kezar Life Sciences. Primary endpoints: Adverse Events at 20 months, Dose-Limiting Toxicities at 28 days and 2 more. Started Sep 2021; status: terminated.
02
Drugs
kzr-261
03
Conditions
melanomaUveal melanoma (UM)mesotheliomacolorectal cancer (CRC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05047536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047536.